UNSPSC 51284039: Oxytetracycline hydrochloride

This classification denotes a tetracycline antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4U7K4N52ZM. European Medicines Agency schedules Oxytetracycline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14740MIG. Oxytetracycline hydrochloride generally arises in the molecular formula C22H24N2O9.CLH. The term 'oxytetracycline hydrochloride' is a U.S. Pharmacopeial Convention designation.

UNSPSC 51284039 Oxytetracycline hydrochloride is a Commodity code, but the recent state and local opportunities tagged under it show minimal activity directly aligned with the code's pharmaceutical-ingredient scope. The four recent solicitations span naloxone and drug deactivation systems, a direct-to-manufacturer prescription program RFI, medical and first aid supplies for fire rescue, and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle. Only the Minnesota cooperative purchasing opportunity and the Texas HHS RFI touch on pharmaceutical procurement broadly; the naloxone and Tampa fire rescue bids are health-related but do not target oxytetracycline specifically. The issuing bodies include county health departments (Seminole County, Florida), state HHS commissions (Texas), city procurement offices (Tampa), and cooperative purchasing alliances (Minnesota MMCAP serving multiple states including Oregon). This mix suggests the code may be underutilized or mislabeled in the recent posting activity, as genuine oxytetracycline procurement—typically an antibiotic for animal health or niche human pharmaceutical applications—does not appear in the available records.

Activity spans Florida, Texas, Minnesota, and Oregon, reflecting both state-level and local/regional procurement. The most concrete pharmaceutical solicitations are the Minnesota MMCAP RFP (S1070000015802, RFP, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, and the Texas HHS Commission RFI (HHS0017013, RFI, due April 3, 2026) for direct-to-manufacturer prescription capabilities. The Tampa Fire Rescue medical supplies IFB (26P00145, due March 13, 2026, estimated contract $700,000) and the Seminole County naloxone procurement (IFB60459723LAS, due July 26, 2023) represent health-sector buying but outside the oxytetracycline family. Given the mismatch between the code's nominal scope and the actual recent opportunities shown, vendors should verify whether their oxytetracycline products are relevant to these solicitations or whether the code assignment reflects a data-quality issue rather than genuine market demand.